Fig. 6

PGE2 mediated the impaired function of sEV-mDCs on ILC2s through EP2/4. PBMCs from patients with AR were co-cultured with allogeneic mDCs, sEV-mDCs, MF63-pretreated sEV-mDCs or combined with MF63 (0.1 μM), ONO/PF (1 μM), anti-IL-10 (2 μg/mL), respectively, for 3 days. A–B. Schematic of MF63-sEV-mDCs induction and blocking experiments. C. The levels of PGE2 in the supernatants of mDCs, sEV-mDCs and MF63-sEV-mDCs (n = 7). D. Intracellular IL-13 levels in ILC2s under different condition were analyzed by flow cytometry. E–H. Percentage of IL-13⁺ILC2s in the culture conditions as described (n = 7). MF63: pharmacological inhibitor of prostaglandin E Synthase; ONO/PF: ONO-AE3-208 and PF-04418948, antagonists for EP2/EP4. Data are shown as mean ± SEM. *P < 0.05, **P < 0.01